BioSpace News Archive

Inceptor Bio, a biotechnology company advancing cell therapies for difficult-to-treat cancers, today announced the closing of a $37 million Series A financing led by Kineticos Ventures.

BridGene Biosciences, Inc. today announced that Wolf Ruprecht Wiedemeyer, Ph.D., biology director at BridGene Biosciences, will be presenting at the inaugural Hippo Pathway Targeted Drug Development Summit 2022, being held by Hanson Wade at the DoubleTree Suites by Hilton Hotel Boston - Cambridge on May 24-26, 2022.

Umoja Biopharma, Inc. announced data from three presentations at the American Society of Gene and Cell Therapy Annual Meeting on its scalable, off-the-shelf in vivo lentiviral vector-based platform, termed VivoVec, that has the potential to achieve efficient T cell transduction upon direct administration to patients.

NANO-X IMAGING LTD (NASDAQ: NNOX) (“ Nanox ” or the “ Company ”), an innovative medical imaging technology company, today announced results for the first quarter ended March 31, 2022.

AIM ImmunoTech Inc. announced that Thomas K. Equels, M.S. J.D., Chief Executive Officer of AIM, will present at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022 in Miami, FL and virtually.

Amedisys, Inc., a leading provider of home health, hospice, personal care and high-acuity care, has been selected by Modern Healthcare as one of the 2022 Best Places to Work in Healthcare for the second consecutive year.

Nemaura Medical, Inc. announces that CEO Dr. Faz Chowdhury will present virtually at the H.C. Wainwright Global Hybrid Investment Conference.

Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced financial results for the fiscal fourth quarter and year ended March 31, 2022 and provided a business update.

Sterigenics®, a business of Sotera Health, and a global leader in comprehensive sterilization services, announced the beginning of processing at its expanded electron beam facility located in Columbia City, Indiana.

I-Mab (the “Company”) (Nasdaq” IMAB), today announced that it will hold a call with investors at 8 a.m. EST on May 27th to present preliminary data from an ongoing phase 2 clinical trial of its differentiated CD73 antibody uliledlimab (also known as TJD5, or TJ004309) and the global clinical development plan.